Glucagonoma is a rare pancreatic alpha-cell tumor that produces a distinctive syndrome of mild diabetes, necrolytic migratory erythema, deep vein thrombosis, weight loss, and depression. Diagnosis combines markedly elevated plasma glucagon with imaging; surgical resection offers the best chance of cure, while medical therapies control advanced disease.
What Glucagonoma Is
Glucagonoma belongs to the family of functional pancreatic neuroendocrine tumors (pNETs). It is rare — fewer than 1 case per 20 million people per year. About 80 percent are malignant by the time of diagnosis, with most having already metastasized, typically to the liver.
- Arises from glucagon-producing alpha cells of pancreatic islets
- Most occur in the body or tail of the pancreas, where alpha cells predominate
- Mean age at diagnosis is 50 to 60 years
- Slight female predominance
- Most cases sporadic; about 5 to 10 percent are associated with MEN1
Why Glucagonoma Causes Diabetes
Glucagon is the principal counterregulatory hormone opposing insulin. Chronic excess produces:
- Increased hepatic glycogenolysis and gluconeogenesis
- Decreased peripheral glucose uptake
- Increased amino acid catabolism (driving hypoaminoacidemia)
- Lipolysis and ketogenesis
Roughly 80 percent of patients have diabetes, usually mild and often manageable with metformin or oral agents — overt ketoacidosis is uncommon because endogenous insulin is preserved. The combination of new mild diabetes with a characteristic migratory rash should raise suspicion. For broader context, see complications and related conditions.
The Glucagonoma Syndrome — the “4 Ds”
| “D” | Feature | Approximate Frequency |
|---|---|---|
| Dermatitis | Necrolytic migratory erythema | ~70 to 90 percent |
| Diabetes | Mild type 2-like diabetes | ~80 percent |
| DVT | Deep vein thrombosis and pulmonary embolism | ~30 percent |
| Depression | Mood and cognitive disturbance | ~50 percent |
Other features include weight loss (often substantial), normocytic anemia, glossitis, stomatitis, cheilitis, alopecia, low plasma amino acid levels (hypoaminoacidemia), and diarrhea.
Necrolytic Migratory Erythema
Necrolytic migratory erythema (NME) is the dermatologic hallmark of glucagonoma. It is seen in approximately 70 to 90 percent of patients and is often the presenting feature that prompts workup.
- Erythematous, often serpiginous plaques
- Distribution: lower abdomen, groin, perineum, buttocks, thighs, perioral and acral areas
- Lesions evolve through redness, blistering, erosion, and crusting
- Different stages coexist as the rash “migrates”
- Pruritus, pain, and superinfection are common
- Often misdiagnosed for months or years as eczema, candidiasis, or psoriasis
The proposed mechanism is multifactorial — amino acid and zinc deficiency, essential fatty acid deficiency, and direct glucagon effects on the skin.
How Clinicians Diagnose Glucagonoma
- Fasting plasma glucagon — often more than 500 to 1,000 pg/mL (normal less than ~150 pg/mL); levels above 1,000 are highly suggestive
- Chromogranin A — usually elevated
- Plasma amino acid panel — characteristic broad reduction in amino acids
- Zinc and essential fatty acid levels
- Complete blood count and basic metabolic panel
- Lipid panel and A1C — see A1C levels
- Multiphase pancreas-protocol CT or MRI
- 68Ga-DOTATATE PET/CT (high sensitivity for somatostatin-receptor-expressing tumors)
- Endoscopic ultrasound with biopsy for small or uncertain lesions
- Skin biopsy of NME — confirms the dermatologic diagnosis
- Genetic testing for MEN1 in younger patients or with relevant family history
Differential Diagnosis
| Condition | Distinguishing Features |
|---|---|
| Type 2 diabetes | No rash, normal glucagon, no weight loss out of proportion |
| Zinc deficiency (acrodermatitis enteropathica) | Periorificial rash, low serum zinc, responds to zinc replacement |
| Pellagra | Photodistributed rash, niacin deficiency, diarrhea, dementia |
| Cutaneous candidiasis | Satellite pustules, responds to antifungals |
| Other pNETs | Insulinoma, gastrinoma, VIPoma, somatostatinoma — different hormonal syndromes |
| Paraneoplastic syndromes | Various, depending on underlying tumor |
Treatment
Treatment depends on disease stage:
- Surgical resection — first-line for localized disease; distal pancreatectomy is most common because of tumor location
- Liver-directed therapy — debulking surgery, radiofrequency ablation, transarterial embolization or chemoembolization for hepatic metastases
- Somatostatin analogs — octreotide LAR, lanreotide depot — reduce glucagon secretion and often dramatically improve NME, mood, and constitutional symptoms
- Peptide receptor radionuclide therapy (PRRT) — 177Lu-DOTATATE for somatostatin-receptor-positive disease
- Targeted therapy — everolimus, sunitinib
- Chemotherapy — temozolomide-based regimens, streptozotocin combinations
- Supportive care — amino acid and zinc supplementation, anticoagulation for venous thromboembolism, nutrition support, antidepressants, glucose control
Diabetes Management in Glucagonoma
- Most patients respond to oral agents alone — see treatment
- Metformin is reasonable first-line in the absence of contraindications
- Avoid sulfonylureas in patients with unintended weight loss or poor nutrition
- Insulin is rarely required and dosing should be cautious because endogenous insulin is preserved
- Address protein-energy malnutrition with dietitian input — see diet and nutrition
- Treat any reversible contributors (corticosteroids, infection) as in standard diabetes care
Thromboembolic Risk
Up to a third of patients experience deep vein thrombosis or pulmonary embolism. Mechanisms include direct prothrombotic effects of glucagon and the underlying malignancy. Hospitalized patients should receive pharmacologic thromboprophylaxis unless contraindicated, and a low threshold for diagnostic imaging is appropriate when new leg swelling or dyspnea develops.
Prognosis
Overall 5-year survival is approximately 50 to 60 percent. Outcomes are substantially better for completely resected disease and worse for metastatic presentations. Long-term follow-up is needed because of late recurrence; surveillance combines clinical assessment, biochemical markers, and periodic imaging.
When to See a Doctor
- A migratory, recurrent rash that has not responded to standard treatments
- Unexplained weight loss with new mild diabetes
- Unprovoked deep vein thrombosis or pulmonary embolism
- Persistent anemia or glossitis with no other obvious cause
- Family history of MEN1 or pancreatic neuroendocrine tumors
- Pancreatic mass found on imaging done for another reason
The Bottom Line
Glucagonoma is a rare pancreatic alpha-cell tumor that produces a recognizable syndrome of mild diabetes, necrolytic migratory erythema, depression, and venous thromboembolism. Because the rash is often the first clue, dermatologic recognition can accelerate diagnosis. Treatment depends on stage — surgical resection for localized disease, somatostatin analogs and other therapies for advanced disease. Talk to your doctor and request endocrinology and oncology referral for any suspected pancreatic neuroendocrine tumor.
